Acetylsalicylic Acid Dimers Blocking C3 Convertase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for complement-mediated disorders often fail to effectively inhibit aberrant complement activation, leading to self-damage and tissue damage in mammals, particularly in chronic inflammatory and degenerative conditions.
Innovation Solution
Development of dimers of acetyl salicylic acid, such as 4,4′-diacetoxy-[1,1′-biphenyl]-3,3′-dicarboxylic acid (DAS-1) and 5,5′-methylenebis(2-acetoxybenzoic acid) (DAS-2), which selectively block the C3 convertase stage of the alternative complement pathway and prevent formation of the membrane attack complex, thereby reducing tissue damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat complement-mediated disorders, then treatment is provided, but they fail to effectively inhibit aberrant complement activation leading to tissue damage
Solution Approach 1:
The patent modifies the chemical structure of acetyl salicylic acid by dimerizing it through various linkers (direct bond, methylene bridge, alkylene chains, aromatic rings) to create compounds with enhanced complement inhibition activity. This structural parameter change transforms a weak inhibitor into a potent therapeutic agent that effectively blocks C3 convertase and prevents membrane attack complex formation, thereby resolving the contradiction between treatment provision and effectiveness.
2Object-affected harmful factors
If dimers of acetyl salicylic acid are used to block C3 convertase and prevent membrane attack complex formation, then complement-mediated tissue damage is reduced, but the complexity of the therapeutic compound increases
Solution Approach 1:
The dimeric structure consists of two acetyl salicylic acid units connected by simple linkers, allowing each monomer unit to contribute to the overall binding affinity and inhibition mechanism. This segmentation provides multiple interaction points with complement proteins, enhancing inhibition effectiveness while maintaining a relatively simple modular structure that is easier to understand and optimize compared to completely novel complex molecules.
Data Source
AI summary
Dimers of acetyl salicylic acid, including 4,4′-diacetoxy-[1,1′-biphenyl]-3,3′-dicarboxylic acid (DAS-1) and 5,5′-methylenebis(2-acetoxybenzoic acid) (DAS-2) are provided. Methods of blocking the C3 convertase stage of the alternative complement pathway, preventing formation of the membrane attack complex of complement, and preventing or treating a complement-mediated disorder in a mammal including the step of administering dimers of acetyl salicylic acid are also provided.